lassa
viru
lasv
origin
isol
nurs
lili
pinneo
strain
lp
nosocomi
outbreak
mission
hospit
citi
jo
northcentr
nigeria
electron
microscopi
lasvinfect
vero
cell
reveal
morpholog
similar
prototyp
arenaviru
lymphocyt
choriomening
viru
lcmv
current
lasv
belong
old
world
group
ow
lcmvlasv
serocomplex
genu
mammarenaviru
arenavirida
famili
persist
infect
mastomi
natalensi
main
sourc
natur
lasv
infect
human
rodenttohuman
transmiss
occur
inhal
dust
contamin
excreta
infect
rodent
direct
contact
abrad
skin
contamin
materi
ingest
contamin
food
cluster
infect
natalensi
respons
spatial
distribut
lassa
fever
lf
case
endem
area
lasv
infect
confin
predominantli
natalensi
monophylogen
group
ai
west
africa
wherea
phylogroup
central
southern
african
region
associ
nonpathogen
ow
arenavirus
mopeia
mopv
morogoro
morv
gairo
gaiv
luna
lunv
detect
lasv
eastern
nigeria
natalensi
phylogroup
aii
occupi
territori
extend
eastern
congo
underlin
potenti
lasv
infect
genet
relat
host
speci
expand
geograph
distribut
addit
isol
lasv
mastomi
erythroleucu
hylomyscu
pamfi
guinea
nigeria
respect
suggest
hostswitch
event
potenti
contribut
lasv
geograph
expans
lasvendem
area
cover
sierra
leon
sl
liberia
guinea
nigeria
ivori
coast
togo
benin
ghana
atrisk
popul
high
million
peopl
moreov
west
africa
undergo
rapid
demograph
environment
chang
like
increas
lasv
spillov
event
come
decad
estim
global
burden
lf
highest
among
viral
hemorrhag
fever
except
dengu
fever
lasv
human
infect
asymptomat
caus
mild
flulik
ill
result
manifest
ill
progress
sever
multiorgan
failur
hypovolem
sepsislik
shock
death
overal
estim
mortal
rate
rural
lasv
infect
among
hospit
patient
vulner
group
women
late
pregnanc
children
year
individu
immun
defici
lf
fatal
higher
lasv
infect
larg
ignor
public
health
threat
howev
histor
high
mortal
among
laboratoryconfirm
lf
case
report
nigeria
trigger
reevalu
lf
risk
global
health
secur
world
health
organ
identifi
lasv
topprior
pathogen
fasttrack
research
vaccin
develop
januari
middl
april
suspect
lf
case
report
across
state
nigeria
fatal
among
confirm
case
prompt
declar
public
health
emerg
lasv
biseg
singlestrand
negativesens
rna
genom
larg
l
rna
encod
l
protein
rnadepend
rna
polymeras
matrix
z
protein
small
rna
encod
nucleoprotein
np
envelop
glycoprotein
precursor
gpc
process
infect
cell
stabl
signal
peptid
ssp
matur
attach
fusion
glycoprotein
molecular
date
indic
lasv
origin
nigeria
year
ago
gradual
move
westward
initi
phylogenet
analysi
reveal
lasv
sequenc
cluster
geograph
independ
rodent
human
sourc
form
four
major
phylogenet
lineag
lineag
compris
lasv
strain
isol
differ
geograph
area
nigeria
largest
lineag
lineag
iv
prototyp
jo
includ
strain
guinea
liberia
sl
genet
analysi
clinic
lf
sampl
collect
confirm
exist
four
major
lasv
lineag
provid
addit
evid
high
lasv
genet
divers
l
rna
segment
respect
lineag
v
sister
relationship
lineag
iv
propos
lasv
isol
mali
ivori
coast
addit
togo
isol
mosaic
genom
structur
l
segment
relat
clade
ii
segment
relat
lineag
iv
propos
repres
separ
lineag
vi
evid
lasv
recombin
present
far
natur
occur
lasv
reassort
seem
rare
event
sinc
three
reassort
identifi
among
lasv
rna
clinic
sampl
lasv
geographybas
cluster
suggest
multipl
infect
individu
travel
across
differ
lasvendem
area
like
explan
observ
lasv
reassort
lasv
anim
studi
carri
jo
josrel
strain
lineag
iv
accordingli
limit
knowledg
pathogen
nigerian
strain
guinea
pig
nonhuman
primat
nhp
pose
obstacl
lasv
vaccin
develop
lasvjo
lineag
iv
lineag
ii
highli
pathogen
strain
guinea
pig
howev
prototyp
lasvlp
lineag
caus
fatal
diseas
anim
lineag
iii
lethal
outbr
guinea
pig
wherea
wildtyp
lasvjo
kill
outbr
guinea
pig
notabl
poor
correl
clinic
outcom
lf
human
virul
lasv
guinea
pig
lasvjo
highli
pathogen
nhp
reproduc
major
biolog
marker
fatal
human
lf
case
howev
recent
lasvjosrel
isol
case
lf
mali
less
pathogen
cynomolgu
macaqu
lasv
strain
sl
liberia
lineag
ii
nigerian
strain
test
nhp
caus
fatal
diseas
predomin
liver
involv
line
recent
clinic
report
experiment
arenavirusinduc
liver
patholog
character
abort
hepatocyt
prolifer
upregul
addit
lasv
receptor
figur
clinic
studi
sl
liberia
establish
fever
pharyng
retrostern
pain
proteinuria
best
predictor
lf
wherea
best
predictor
outcom
fever
sore
throat
vomit
elev
level
aspart
aminotransferas
ast
plasma
high
viremia
strongli
associ
death
high
aspart
astalanin
aminotransferas
astalt
ratio
suggest
substanti
involv
nonhepat
tissu
lf
pathogenesi
low
undetect
level
proinflammatori
chemokin
interferon
ifn
induc
protein
elev
level
tumor
necrosi
factoralpha
receptor
associ
fatal
lf
high
plasma
consid
biolog
marker
fatal
lf
link
liver
patholog
regener
likewis
low
level
ast
alt
alkalin
phosphatas
blood
urea
nitrogen
lf
patient
sl
correl
surviv
termin
stage
lf
character
sever
pulmonari
edema
acut
respiratori
distress
sign
encephalopathi
observ
coma
seizur
retrospect
studi
small
cohort
patient
lf
treat
jo
hospit
northcentr
nigeria
confirm
fever
hemorrhag
manifest
cough
proteinuria
retrostern
pain
clinic
predictor
lf
transmiss
season
patient
lf
predominantli
urban
area
fever
lead
clinic
sign
wherea
bleed
diathesi
abdomin
pain
headach
present
confirm
case
recent
studi
larger
cohort
patient
lf
treat
irrua
specialist
teach
hospit
edo
state
nigeria
reveal
similar
differ
lf
sl
nigeria
group
patient
liver
patholog
manifest
nigerian
patient
often
lower
astalt
ratio
consist
hepatocyt
involv
group
higher
viral
load
strongli
correl
poor
outcom
howev
contrast
sl
lf
sepsisassoci
hypothermia
rather
fever
predictor
poor
outcom
nigerian
patient
lf
patient
younger
older
like
die
kidney
patholog
manifest
high
creatinin
urea
blood
level
one
notabl
clinic
featur
nigerian
lf
analysi
nigerian
lasv
strain
reveal
differ
lasv
genet
lineag
epidemiolog
diseas
compar
previou
year
reason
recent
lf
increas
nigeria
clear
potenti
relat
chang
rodent
reservoir
improv
diagnost
public
awar
sensorineur
hear
loss
snhl
seem
common
featur
lasv
infect
west
africa
individu
experienc
deaf
lasvspecif
antibodi
versu
match
control
murin
model
snhl
lasv
isol
fatal
nonleth
human
case
affect
cochlear
hair
cell
induc
degener
spiral
ganglion
cell
auditori
nerv
model
provid
valuabl
insight
mechan
snhl
human
nhp
survivor
recent
studi
document
presenc
sever
vascular
lesion
inner
ear
tissu
studi
involv
lf
survivor
valid
anim
model
lasv
infect
indic
earli
robust
virusspecif
tcell
respons
best
correl
protect
neutral
antibodi
appear
late
infect
low
titer
moreov
individu
experienc
subclin
mild
form
lf
suscept
reinfect
lasv
longterm
protect
lf
diseas
notabl
lf
survivor
guinea
strong
memori
tcell
respons
conserv
epitop
np
lasvjo
nigerian
lasv
strain
nevertheless
potent
lasv
neutral
monoclon
antibodi
isol
lf
survivor
antibodi
protect
anim
model
lf
consequ
replicationcompet
deepli
attenu
vaccin
capabl
induc
right
combin
cellular
humor
respons
would
prefer
candid
lasv
genet
divers
great
challeng
design
univers
prevent
lf
vaccin
one
three
predict
crossreact
lasvgpc
tcell
epitop
share
lasvjo
lineag
iv
lineag
iii
cell
josimmun
transgen
mice
recogn
gpc
epitop
howev
studi
vaccin
candid
reassort
carri
l
rna
mopv
rna
lasvjo
encod
major
protect
antigen
np
gpc
provid
first
evid
support
feasibl
panlasv
vaccin
express
np
import
featur
contribut
crossprotect
consist
observ
npspecif
cell
play
major
role
viru
control
mice
infect
lcmv
lf
survivor
strong
tcell
respons
recogn
conserv
variabl
epitop
lasv
np
find
suggest
antinp
respons
earli
stage
effect
control
infect
contribut
crossprotect
immun
singl
immun
fulli
protect
guinea
pig
marmoset
fatal
diseas
caus
lasvjo
lineag
iv
nigerian
strain
lineag
ii
rhesu
macaqu
day
immun
spleen
cell
secret
stimul
distantli
relat
lcmv
lasv
share
sequenc
homolog
lcmv
includ
conserv
np
gpc
tcell
epitop
howev
macaqu
challeng
strain
lcmv
die
lflike
diseas
wherea
primat
includ
simian
immunodefici
viru
siv
infect
monkey
protect
fatal
lflike
diseas
result
indic
safe
immunogen
induc
broad
tcellmedi
crossprotect
immun
among
avail
lasv
vaccin
candid
safeti
immunogen
sivinfect
rhesu
macaqu
model
human
infect
uniqu
featur
west
africa
lfendem
area
exampl
nigeria
also
high
hiv
seropreval
import
determin
whether
vaccin
could
safe
context
infect
releas
target
product
profil
tpp
lasv
vaccin
emphas
prevent
use
vaccin
highest
prioriti
optim
candid
vaccin
fulfil
follow
criteria
whoaccept
safetyreactogen
ii
inject
singledos
regimen
iii
high
efficaci
prevent
infect
diseas
caus
lasv
lineag
iv
iv
confer
longlast
year
protect
sever
virusvector
vaccin
candid
base
vaccinia
viru
recombin
vesicular
stomat
viru
rvsv
mopv
yellow
fever
alphaviru
replicon
test
proofofconcept
studi
nhp
tabl
among
rvsvlasvgpc
recommend
acceler
vaccin
develop
intern
vaccin
expert
exhibit
uniqu
featur
meet
tpp
criteria
safeti
avail
anim
model
lf
includ
immunocompromis
nhp
ii
induct
singl
shot
protect
steril
tcell
respons
sl
nigerian
strain
lasv
respons
ongo
outbreak
nigeria
iii
genet
stabil
vivo
vitro
iv
efficaci
postexposur
applic
v
favor
thermost
low
dose
plaqueform
unit
requir
induct
protect
immun
make
vaccin
attract
manufactur
dose
rang
natur
infect
dose
rodenttohuman
transmiss
present
lasv
np
cpcderiv
epitop
major
histocompat
complex
mhc
molecul
effect
way
induc
robust
crossprotect
tcell
respons
deplet
cell
anim
complet
abolish
protect
wherea
cell
partial
effect
recombin
recent
rescu
cdna
clone
figur
arenaviru
triseg
technolog
would
allow
gener
express
addit
lasv
antigen
expand
crossprotect
rang
lasv
vaccin
exampl
express
gpc
np
antigen
distantli
relat
lineag
lasvlp
revers
genet
also
use
gener
attenu
mopv
disrupt
exonucleas
exo
domain
np
requir
antiifn
activ
lasvjo
gpc
gene
clone
express
mopvac
singl
immun
mopevac
lasv
fulli
protect
nhp
homolog
lethal
challeng
howev
disrupt
np
exo
result
yield
reduct
mopevac
lasv
product
cultur
cell
combin
requir
high
dose
focusform
unit
pose
obstacl
manufactur
develop
vaccin
candid
singl
inject
rvsvlasvgpc
experiment
vaccin
lasvgpc
substitut
vsvg
fulli
protect
guinea
pig
nhp
lasv
strain
lineag
immun
induc
detect
level
tcell
respons
challeng
low
humor
respons
igg
enzymelink
immunosorb
assay
found
three
four
vaccin
anim
lasv
challeng
neutral
antibodi
detect
four
macaqu
coalit
epidem
prepared
innov
cepi
http
cepinet
recent
creat
nonprofit
organ
acceler
vaccin
develop
emerg
epidem
infect
commerci
market
insuffici
justifi
privat
invest
cepi
support
develop
vaccin
candid
late
preclin
stage
phase
ii
stockpil
emerg
use
cepi
initi
wide
welcom
support
multipl
govern
philanthrop
organ
industri
partner
develop
lasv
vaccin
includ
aggress
cepi
busi
plan
goal
test
safeti
efficaci
human
phase
iiab
trial
stockpil
one
first
lasv
vaccin
candid
support
cepi
develop
themi
bioscienc
base
recombin
measl
vaccin
technolog
institut
pasteur
wwwthemisbiocom
measl
viru
vectorbas
vaccin
platform
look
promis
human
infect
antibodybas
protect
howev
peerreview
preclin
data
support
applic
platform
develop
lf
vaccin
predomin
tcellmedi
mechan
protect
preexist
antivector
immun
might
affect
outcom
clinic
studi
address
approach
cepi
also
support
dnabas
vaccin
lasv
rais
feasibl
question
dna
prevent
vaccin
licens
human
use
scientif
interest
dna
vaccin
endeavor
decreas
difficulti
improv
dna
immunogen
advanc
plasmid
formul
deliveri
requir
see
first
licens
dna
vaccin
peopl
next
year
lasv
infect
easi
target
dna
vaccin
sinc
includ
vaccin
formul
electropor
lasvgpc
dna
induc
modest
level
neutral
antibodi
provid
addit
evid
tcell
respons
play
major
role
protect
nhp
two
addit
cepi
award
announc
support
rvsvbase
lasv
vaccin
base
platform
appli
design
vaccin
test
ring
vaccin
trial
guinea
appear
provid
protect
efficaci
remain
determin
clinic
studi
document
side
effect
associ
vaccin
includ
postvaccin
arthriti
detect
vector
rna
blood
infecti
vaccin
viru
skin
vaccin
individu
anim
studi
alway
line
ebola
viru
ebov
vaccin
clinic
trial
suggest
immun
correl
protect
univers
depend
vaccin
platform
vaccin
regimen
host
genet
preexist
immun
immun
schedul
challeng
protocol
lesson
ebov
vaccin
develop
applic
lasv
sinc
depend
vaccin
platform
vaccin
recipi
document
tabl
second
rvsvbase
lasv
vaccin
candid
support
cepi
base
vesiculovax
platform
licens
profectu
bioscienc
platform
develop
improv
safeti
rvsv
vector
n
gene
transloc
truncat
vsvg
cytoplasm
tail
attenu
vector
immunogen
nhp
induc
mild
inflammatori
respons
intrathalam
inocul
vector
use
gener
experiment
vaccin
express
singl
multipl
gp
protect
nhp
ebov
marv
challeng
peerreview
preclin
data
support
lasv
vaccin
base
vesiculovax
platform
likewis
cepi
support
preclin
develop
lasvgpcbas
vaccin
vector
nonrepl
simian
adenoviru
evid
support
suitabl
platform
control
lf
basi
natur
histori
diseas
mechan
protect
immun
protect
nigerian
strain
lasv
critic
requir
lasv
vaccin
prequalif
requir
rais
high
bar
vaccin
develop
emphas
whopref
vaccin
candid
prevent
costeffect
measur
gener
popul
endem
area
among
current
avail
lasv
vaccin
candid
shown
protect
lasv
strain
lineag
ii
respons
current
lf
outbreak
nigeria
stockpil
emerg
use
workabl
concept
infect
unknown
epidemiolog
unpredict
outbreak
exampl
ebov
nipah
sever
acut
respiratori
syndrom
poorli
justifi
case
lasv
endem
area
well
defin
natur
reservoir
key
rout
human
transmiss
known
populationbas
vaccin
effect
option
control
lf
endem
area
success
stori
candid
liveattenu
vaccin
argentin
hemorrhag
fever
provid
guidelin
lasv
vaccin
clinic
develop
high
lasv
genet
divers
multicent
trial
sever
endem
area
countri
would
probabl
requir
evalu
crossprotect
efficaci
vaccin
candid
preexist
lasv
immun
potenti
affect
vaccin
dosedepend
respons
appropri
effort
must
appli
human
trial
design
correctli
assess
vaccin
immunogen
root
research
collabor
capac
build
crucial
anticip
multicent
immunogen
efficaci
trial
west
africa
whopref
lasv
vaccin
cover
adult
pediatr
popul
seem
reason
plan
pediatr
studi
success
complet
phase
ii
trial
adult
pediatr
studi
subject
special
provis
clinic
trial
regul
howev
note
replicationcompet
us
food
drug
administr
fda
approv
pediatr
vaccin
includ
reassort
influenza
flumist
medimmun
humanbovin
rotaviru
rotateq
merck
vaccin
safeti
efficaci
vaccin
children
infant
indic
reassort
vaccin
platform
well
suit
pediatr
popul
lasv
vaccin
safe
children
well
sinc
safeti
immunogen
sivinfect
rhesu
macaqu
alreadi
document
fda
recommend
replicationcompet
vaccin
pregnant
women
lf
risk
group
high
fatal
rate
especi
third
trimest
pregnanc
replicationdefici
modifi
vaccinia
ankara
vector
gener
lasvlik
particl
mvavlp
geovax
lab
inactiv
recombin
vaccin
candid
express
lasvgpc
rabi
vaccin
vector
lassarab
potenti
consid
vaccin
candid
group
risk
current
vaccin
earli
preclin
step
develop
cepi
lasv
vaccin
portfolio
base
differ
featur
vaccin
platform
rather
natur
histori
diseas
ration
vaccin
design
headtohead
comparison
lasv
vaccin
candid
valid
nhp
model
supervis
unbias
intern
recogn
expert
assess
crossprotect
breadth
seem
reason
step
go
expens
clinic
phase
ii
trial
comparison
combin
phase
safeti
data
provid
valuabl
inform
clinic
develop
target
differ
group
risk
endem
area
west
africa
